Published in final edited form as:

Antiviral Res. 2012 December ; 96(3): 296–304. doi:10.1016/j.antiviral.2012.09.021.

Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr Virus

R. Goswami¹, S. Gershburg¹, A. Satorius¹, and E. Gershburg^{1,*}

¹Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield IL, 62794-9626

Abstract

Signaling pathways mediating Epstein-Barr virus (EBV) reactivation by Ag-bound B-cell receptor (BCR) were analyzed using a panel of 80 protein kinase inhibitors. Broad range protein kinase inhibitors Staurosporin, K252A, and PKC-412 significantly reduced the EBV genome copy numbers measured 48 hours after reactivation perhaps due to their higher toxicity. In addition, selected inhibitors of the phosphatidylinositol-3-kinase (PI3K), protein kinase C (PKC), mitogen-activated protein kinase (MAPK) and nuclear factor κ B (NF- κ B) pathways, glycogen synthase kinase 3 β (GSK-3 β), platelet-derived growth factor receptor-associated tyrosine kinase (PDGFRK), and epidermal growth factor receptor-associated tyrosine kinase (EGFRK) significantly reduced the EBV genome copy numbers as well. Of those, only U0126 and Erbstatin analog, which inhibit MAPK pathway and EGFRK respectively, did not inhibit viral reactivation assessed by expression of the EBV early protein, EA-D. None of the tested compounds, except for K252A, affected the activity of the EBV-encoded protein kinase *in vitro*. These results show that EBV reactivation induced by BCR signaling is mainly mediated through PI3K and PKC, whereas MAPK might be involved in later stages of viral replication.

Keywords

Epstein-Barr virus (EBV); protein kinase inhibitors (PKI); signal transduction; EBV BGLF4 protein kinase; viral reactivation

1. INTRODUCTION

Over 90% of the world population is infected with Epstein-Barr virus (EBV) by adulthood. Like other herpesviruses, EBV has a biphasic life cycle which includes latent and lytic programs. Upon primary infection, the virus establishes a lifelong latency in memory B lymphocytes characterized by a highly restricted gene expression and lack of virion production (Kieff and Rickinson, 2007). A variety of EBV-associated malignancies are linked to the viral latency (Rickinson and Kieff, 2007). Various stimuli may activate viral lytic program in latently infected cells leading to a coordinated expression of majority of viral genes and production of progeny virions (Kieff and Rickinson, 2007). This phase of

© 2012 Elsevier B.V. All rights reserved.

* corresponding author: Edward Gershburg Department of Medical Microbiology, Immunology and Cell Biology Southern Illinois University School of Medicine 825 N. Rutledge Street room 2620 Springfield IL, 62794-9626 USA Phone: (217) 545-1139 egershburg@siumed.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

infection is clinically associated with infectious mononucleosis and oral hairy leukoplakia (Rickinson and Kieff, 2007).

Of the different ways to reactivate the lytic program *in vitro*, treatment with anti-Ig antibodies seems to be more physiologically relevant since it mimics B-cell Ag-receptor (BCR) signaling (Iwakiri and Takada, 2004; Takada, 1984; Tovey et al., 1978). Upon Ag binding, BCR aggregates and activates protein tyrosine kinases Lyn, a member of Src family of tyrosine kinases, and Syk. Simultaneously, Ag binding causes activation of phosphatidylinositol-3-kinase (PI3K) (through BCR co-receptor CD19), which, along with Lyn and Syk, is involved in activation of Bruton's tyrosine kinase (Btk). Once Lyn, Syk, and Btk are activated, the signal is further propagated through activation of phospholipase C $\gamma 2$ (PLC $\gamma 2$). PLC $\gamma 2$ hydrolyzes phosphatidylinositol diphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 generation causes the mobilization of Ca^{2+} ions required for the activation of several transcription factors (such NF- κB), whereas DAG activates conventional protein kinase C (PKC) isotypes which regulate mitogen-activated protein kinase (MAPK) family. The family consists of three members: extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 MAPK (Johnson and Lapadat, 2002). Following activation, these kinases phosphorylate different sets of transcription factors, which then regulate expression of certain genes. Other similar 'downstream' effectors are Akt (or protein kinase B) and Ca^{2+} -calmodulin. Eventually, a complex interplay between the pathways induced in BCR signaling translates into a well-balanced system that ensures proper cell responses to a variety of conditions (Dal Porto et al., 2004; Kurosaki et al., 2010).

In addition to cellular protein kinases, herpesviruses and several other large DNA viruses (poxviruses, baculoviruses), encode their own protein kinases. These protein kinases appear to target multiple viral and cellular proteins coordinating different aspects of viral replication (Gershburg and Pagano, 2008; Jacob et al., 2011). Lymphotropic herpesviruses, such as EBV, encode only one protein kinase (the BGLF4 gene product), which is a member of conserved herpesvirus protein kinase (CHPK) family (Gershburg and Pagano, 2008; Kawaguchi and Kato, 2003). Kinases in this group are tegument proteins (Asai et al., 2006; Overton et al., 1992; van Zeijl et al., 1997) expressed during lytic program and play a crucial role in viral infection, because a knockdown of their expression levels or knockout of their corresponding genes results in significant replication defects (Gershburg et al., 2007; Murata et al., 2009; Prichard et al., 1999). Attempts to inhibit CHPKs using pharmacological inhibitors showed that while human cytomegalovirus (HCMV) pUL97 protein kinase autophosphorylation activity was inhibited by 0.5 μM of non-glycosidic indolocarbazole I (NGIC-I) (Marschall et al., 2002) and by 1 μM of maribavir (MBV) (Biron et al., 2002; Hamirally et al., 2009), these compounds did not inhibit the activity of the purified EBV-PK (Gershburg et al., 2004; Marschall et al., 2002). Noteworthy, however, the latter compound inhibits EBV replication (Gershburg et al., 2004; Wang et al., 2009; Zacny et al., 1999) and causes a loss of the hyperphosphorylated form of an EBV early protein EA-D (Gershburg and Pagano, 2002; Zacny et al., 1999).

Induction of the EBV lytic program in certain Burkitt's lymphoma (BL) cell lines after treatment with anti-Ig antibodies can be viewed as a 'side effect' of the BCR signaling, but these cell lines can serve as an invaluable tool to study pathways responsible for disruption of viral latency. A number of studies demonstrated that activation of PI3K, PKC, MAPK, and NF- κB pathways is crucial for activation of EBV lytic program (Daibata et al., 1990; Darr et al., 2001; Davies et al., 1991; Gao et al., 2001; Iwakiri and Takada, 2004; Lazdins et al., 1987; Mori and Sairenji, 2006; Oussaief et al., 2011; Satoh et al., 1999); however, other reports suggested that inhibition of PI3K or NF- κB pathways facilitates reactivation of lytic program of several gammaherpesviruses (Brown et al., 2003; Liu et al., 2008; Peng et al.,

2010). The present study used a set of protein kinase inhibitors (PKIs) to verify contribution of several signaling pathways in EBV lytic program. The results indicate that inhibition of PI3K, MAPK, NF- κ B pathways, and to some extent cyclin-dependent kinases (CDKs) significantly reduced EBV replication. An effect of these inhibitors on the activity of the EBV-encoded protein kinase was also analyzed, and this analysis showed that only K252A inhibited the EBV-PK activity *in vitro*.

2. MATERIALS AND METHODS

2.1 Reagents

Screen-Well™ Kinase Inhibitor Library was purchased from Enzo Life Sciences and contains 80 known kinase inhibitors supplied dissolved in dimethyl sulfoxide (DMSO) at 10mM (a complete list of compounds can be found on the company's website). After initial screen, selected compounds were purchased from the following suppliers: LY294002, Ro-31-8220, 5-Iodotubercidin, Erbstatin analogue, and Kenpaullone from Cayman Chemicals; Wortmannin, Staurosporine and K252A from LC Laboratories; Rottlerin from Enzo Life Sciences; Bay-11-7082 from Calbiochem; and acyclovir (ACV) from Sigma. All compounds stocks were prepared in DMSO at concentration 10mM and frozen in aliquots. A fresh aliquot was used for each experiment.

2.2 Cell culture

Akata is a Burkitt's lymphoma (BL) cell line latently infected with EBV (Takada et al., 1991). The cells were maintained in RPMI 1640 medium (Gibco, Invitrogen) supplemented with antibiotic/antimycotic mixture (Anti-Anti, Gibco, Invitrogen), MEM non-essential amino acids mixture (Gibco, Invitrogen), 1mM sodium pyruvate (BioWhittaker, Cambrex Bio Science), 2mM L-glutamate (Cellgro), and 10% fetal bovine serum. Cultures were incubated at 37°C in a humidified atmosphere of 5% CO₂ in air. SF9 cells are a subclone of *Spodoptera frugiperda* (Fall Armyworm) IPLB-Sf21-AE cells (Invitrogen). The cells were maintained in Grace's insect medium (Invitrogen) supplemented with 2mM L-glutamate (Cellgro) and 10% fetal bovine serum. For protein expression, the cells were adapted to serum-free suspension culture in Serum-Free (Sf) Insect Culture Medium (Allele Biotechnology) supplemented with 2mM L-glutamate. The cells were cultured at 27°C.

2.3 Viral reactivation and treatment with protein kinase inhibitors

To initiate viral lytic program, exponentially growing cells were pelleted by centrifugation at 500×g and resuspended in fresh medium containing 50µg/mL goat anti-human IgG (F(ab')₂) (Jackson Immunoresearch Laboratories) and 10µM of the inhibitors. Cells treated only with DMSO served as a control for an uninhibited viral reactivation; cells treated with 50µM of ACV served as a control for an efficient inhibition of viral replication.

2.4 Real-time PCR

The quantitative real-time PCR (qPCR) was performed using a TaqMan probe targeting the EBV BamHI fragment, which has previously been described in detail (Fan and Gulley, 2001; Gershburg et al., 2007). Briefly, total genomic DNA was isolated from Akata cells 48 hours after viral reactivation using a DNeasy Blood and Tissue kit (Qiagen). One microliter of this DNA was analyzed by qPCR on a Step-One real-time thermocycler (Applied Biosystems) under the following cycle conditions: 50°C for 2 min (1 cycle), 95°C for 10 min (1 cycle), and 95°C for 15 s and 60°C for 1 min (40 cycles). Viral DNA copy numbers were calculated from external standards of known concentrations of EBV B95-8 DNA (Advanced Biotechnologies Inc., MD). The primers and the probe used for PCR are EBVW-1 (5'-GCAGCCGCCAGTCTCT-3'), EBVW-2 (5'-

ACAGACAGTGCACAGGAGCCT-3'), and EBVW-FAM (5'-FAM [6-carboxyfluorescein]-AAAAGCTGGCGCCCTTGCTG-TAMRA [6-carboxytetramethylrhodamine]-3').

2.5 Cell viability assays

Effects of protein kinase inhibitors on the viability of latently infected Akata cells were measured by CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). For these assays, the cells were seeded at 2×10^5 cells/well in 96-well plates (in triplicates) and treated with different concentrations (0.0005 to 30 μ M) of the selected PKIs. Assay buffer was added 48 hours after treatment for additional 4 hours. The color development was measured on a PowerWave XS plate reader (Bio-Tek) at wavelength 490nm.

2.6 Expression and purification of the GST-tagged EBV protein kinase

The coding sequence of EBV BGLF4 gene (B95-8 strain, Genebank V01555, nucleotides 122,328 – 123,692) was amplified by PCR and inserted into the NcoI and XhoI restriction sites of a modified pFastBacHT vector in which the His₆ tag was replaced with a glutathione S-transferase (GST) tag (pFastBacGST) (generously provided by J. Sondek, University of North Carolina at Chapel Hill). An inactive kinase variant was generated by using site-directed mutagenesis changing an invariant lysine-102 into isoleucine. Recombinant baculoviruses were prepared following the Bac-to-Bac method (Invitrogen).

Recombinant GST-BGLF4 was expressed in SF9 insect cells for 72 hours at 27°C after virus infection. The cells were lysed in 20mM Tris (pH 7.5), 300mM NaCl, 1mM DTT, 0.5% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10% (v/v) glycerol, and Halt protease inhibitor cocktail (Pierce Biotechnology) on a XL-2000 sonicator (Qsonica, LLC). GST-BGLF4 was purified using sequential affinity (GSTrap FF) and ion-exchange (HiTrap DEAE FF) (GE Healthcare) column chromatography steps. Fractions containing the GST-BGLF4 protein were pulled and concentrated in 20mM Tris (pH 7.5), 200mM NaCl, 1mM DTT and 10% (v/v) glycerol for *in vitro* kinase assays.

2.7 In-vitro kinase assays

The kinase assays were performed as previously described (Gershburg et al., 2010) with several modifications. Each reaction contained 1pmole of GST-BGLF4 kinase and 1 μ g of myelin basic protein (MBP) as a substrate in a kinase buffer (75mM Hepes, pH 7.3, 10mM NaCl, 5mM MnCl₂, 1mM dithiothreitol (DTT) and 0.1% NP-40) complemented with 50 μ M ATP (Sigma), 2.5 μ Ci of [γ -³²P]-ATP (specific activity 4,500 Ci/mmol, MP Biomedicals), and 10 μ M of each protein kinase inhibitor or DMSO. The reactions were incubated for 5 min at 37°C in Thermomixer (Eppendorf) and then half of the volume (10 μ l) of each reaction was spotted on a P81 phosphocellulose disc (Whatman). The discs were sequentially washed twice in 75mM H₃PO₄ and once in 95% ethanol and air-dried. The discs were placed in 1 ml of ScintiSafe Econo-1 scintillation liquid (Fisher Scientific) and amounts of incorporated ³²P were measured on a scintillation counter (Beckman-Coulter).

2.8 Immunoblotting

EBV lytic program was reactivated in Akata cells as described above. At 24 hours post reactivation, the cells were collected, washed with PBS, and whole-cell lysates were prepared in RIPA buffer (150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris, pH 8.0) containing Halt protease and phosphatase inhibitor cocktails (Pierce Biotechnology). Cell debris was removed by centrifugation at 14,000rpm for 15 minutes. Then, 5 μ g of the lysates were denatured in Laemmli loading buffer (5 min at 95°C), resolved by SDS-PAGE (10% gels), and transferred onto

nitrocellulose membranes (Millipore). After incubation in blocking buffer [5% Difco skimmed milk (BD Biosciences) in TBST (Tris-buffered saline with 0.2% Tween 20)], the membranes were incubated for 16 hours with anti-EA-D mAb (Bioworld Consulting Laboratories) diluted to 1:1,000 in blocking buffer. The membranes were washed in TBST in incubated for 1 hour with IRDye-800CW-conjugated goat anti-mouse secondary antibody (Li-Cor Biosciences) diluted 1:20,000 in blocking buffer. After additional washes, the proteins of interest were visualized on an Odyssey® Infrared Imaging system (Li-Cor Biosciences). To verify the equal loading, membranes were re-probed with anti- β -actin mAb (Sigma) used at 1:2,000 dilution.

3. RESULTS

3.1 Protein kinase inhibitors (PKIs) that inhibit EBV reactivation in Akata cells

Our initial objective was to investigate whether inhibition of different protein kinases will affect EBV reactivation. To this end, we used a commercial set of protein kinase inhibitors (Screen-Well™ Kinase Inhibitor Library from Enzo Life Sciences) and examined their effect on EBV lytic program in Akata cells. Due to the large number of inhibitors, conditions of the assay were simplified: (a) only one concentration (10 μ M) of PKIs was used, and (b) the inhibitors were added concurrently with the inducer, goat anti-human IgG. The cells were incubated for 48 hours post-induction and EBV genome copy numbers were enumerated in total genomic DNA by qPCR. The data of 3 independent experiments performed in duplicates was processed as follows: (a) in each experiment, genome copy numbers were calculated based on standard curve built using a commercial standard EBV DNA, (b) the number of genomes per nanogram of total genomic DNA was calculated, (c) these concentrations were normalized and expressed as percentage relative to the positive control (cells treated with DMSO), (d) percent values were averaged and expressed as (100–[mean of the 3 experiments]) $\pm$ standard error of mean (sem), p-values were calculated using one sample t-test (Fig. 1). Based on degree of inhibition, the inhibitors were divided into active (over 80% inhibition), partially active (50–79% inhibition), and inactive (less than 50% inhibition); only compounds in the active group were selected for further studies. ACV, a known inhibitor of viral replication, was used at 50 μ M and reduced viral replication by 88 $\pm$ 6%, which is comparable to the cells not treated with IgG (96 $\pm$ 2%).

Staurosporine and K252A are pan-specific protein kinase inhibitors, which affect a wide range of protein kinases and pathways. Therefore, while inhibition of viral replication by these compounds (88 $\pm$ 6% and 92 $\pm$ 6%, respectively) implies that protein kinases play a significant role in viral replication, no specific pathway could be identified. In addition, a number of compounds that inhibit certain pathways more specifically were also found to be effective in inhibiting the EBV replication. LY294002 and Wortmannin are PI3 kinase inhibitors (Arcaro and Wymann, 1993; Vlahos et al., 1994); U0126 inhibits mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) (Favata et al., 1998); Tyrphostin 9 is a platelet-derived growth factor receptor (PDGFR)-associated tyrosine kinase inhibitor (Bilder et al., 1991); PKC412, a staurosporine derivative, inhibits multiple kinases, but its main target is PKC (Fabbro et al., 2000); Ro 31-8220 inhibit PKC and GSK-3 β (Gschwendt et al., 1994; Hers et al., 1999; McKenna and Hanson, 1993); rottlerin, which originally thought to specifically inhibit PKC δ , was later shown to inhibit multiple other kinases (Davies et al., 2000), 5-Iodotubercidin inhibits casein kinase I (CKI), PKC, and ERK2 (Fox et al., 1998; Massillon et al., 1994); erbstatin analog is an epidermal growth factor receptor (EGFR)-associated tyrosine kinase inhibitor (Umezawa et al., 1990); BAY-11-7082 is a nuclear factor κ B (NF- κ B) pathway inhibitor (Pierce et al., 1997); and Kenpaullone inhibits glycogen synthase kinase 3 β (GSK-3 β) and several cyclin-dependent kinases (CDKs) (Schultz et al., 1999; Zaharevitz et al., 1999). Thus, our screen identified or confirmed a

number of protein kinase inhibitors that inhibit EBV replication thereby pointing out that pathways inhibited by these compounds play a role in EBV replication.

3.2 Selectivity of the PKIs inhibiting EBV replication

Next, we asked whether the antiviral effect of the selected PKIs is due to a decrease in cell viability. The cells were incubated with 0.0005-30 μ M of PKIs, which were active in the EBV replication inhibition assay, for 48 hours at which point their metabolic activity was measured by a modified MTS assay (Promega) and EBV genome copy numbers were measured by qPCR. The cytotoxic and inhibitory concentrations inhibiting the cellular activity and viral replication by 50% (CC50 and IC50) were calculated in Prism 5 (GraphPad) using a four parameters sigmoidal dose-response curve and summarized in Table 1. A control treatment with ACV at 50 μ M exhibited no significant effects on cell viability (89 $\pm$ 4% remaining viability relative to DMSO-treated cells) (not shown). As expected, Staurosporine and K252A have had a major effect on cell viability with CC50 values of 0.004 and 0.08 μ M, respectively, because both compounds were previously shown to cause apoptosis (Bertrand et al., 1994; Chin et al., 1999). Likewise, Tyrphostin 9, PKC-412, rottlerin, Ro 31-8220, and 5-iodotubercidin were relatively toxic (CC50 ranging from 0.056 to 1.147 μ M). These compounds (except for 5-iodotubercidin) also induce apoptosis in variety of systems (Bahlis et al., 2005; Han et al., 2000; Palumbo et al., 1997; Ringshausen et al., 2006). Moreover, majority of the compounds were non-selective and had a low therapeutic index (TI) ranging from 1 to 3. Only 3 compounds had a higher TI – U-0126, Wortmannin, and BAY 11-7082 (TI = 13); the TI for Kenpaullone and K252A were 8 and 6 respectively (Table 1). These results indicated that the compounds inhibiting MAPK, PI3K, and NF- κ B pathways (and to some extent, CDKs) were able to inhibit EBV replication with certain degree of selectivity. It should also be noted that while the TI values even for more specific compounds were lower than values reported for other EBV inhibitors (Gershburg et al., 2004; Williams et al., 2003), these data identify pathways intimately involved in EBV reactivation.

3.3 Inhibition of the EBV reactivation vs replication

MAPK, PI3K, NF- κ B pathways have previously been shown to play a significant role in EBV infection (Daibata et al., 1990; Darr et al., 2001; Davies et al., 1991; Gao et al., 2001; Iwakiri and Takada, 2004; Lazdins et al., 1987; Mori and Sairenji, 2006; Oussaief et al., 2011; Satoh et al., 1999). However, no clear distinction has been made as to whether these pathways play a role in viral reactivation or in later steps of the infection. In other words, does the inhibition of these pathways only prevent signal transduction that leads to lytic program initiation or these pathways also function at later steps in viral infection? To distinguish these two possibilities, steady-state levels of an early EBV protein, EA-D, in the presence of 1 and 10 μ M of selected PKIs were analyzed by immunoblotting. This protein is usually detected 6-8 hours after lytic program reactivation and its expression is regulated by EBV immediate-early proteins BZLF1 and BRLF1 (Adamson and Kenney, 1998; Feederle et al., 2000). In the presence of 1 μ M of Staurosporin, K252A, PKC-412, and Wortmannin no EA-D expression was detected (Fig. 2B). In contrast, the same concentration of U-0126, Tyrphostin 9, Ro 31-8220, 5-Iodotubercidin, rottlerin, ebstatin analog, and kenpaullone did not affect the expression of EA-D (Fig. 2B). The effect of BAY 11-7082 and LY294002 was intermediate and mainly affected the levels of a hyperphosphorylated form of the EA-D, whereas treatment with Ro 31-8220 lead to an increased level of this form (top band, Fig. 2B). At 10 μ M the inhibitory effect of all compounds (perhaps with exception of Erbstatin analog) is more pronounced (Fig. 2A). The EA-D expression levels remain relatively high in U-0126 treatment (although visibly lower than at 1 μ M treatment), whereas they are hardly detectable for other treatments. Moreover, at 10 μ M all compounds exhibit significant toxicity (Table 1) as exemplified by the Bay 11-7082, which even affected expression levels

of housekeeping genes (loss of β -actin, Fig. 2A). These results suggest that an active PI3 kinase is essential for reactivation of the EBV lytic program, because its inhibition by an irreversible inhibitor (Wortmannin) completely blocked viral reactivation, while the treatment with suboptimal concentrations of the reversible PI3 kinase inhibitor LY294002 resulted only in partial inhibition (Fig. 2B). The results also suggest that pan-specific inhibitors, such as K252A, also block viral reactivation likely by inhibiting multiple pathways.

3.4 Properties of GST-BGLF4 *in vitro* activities

Treatment with LY294002 and BAY 11-7082 had a more pronounced effect on the levels of the hyperphosphorylated form of EA-D (Fig. 2B). This form is only detected in the presence of an active EBV-encoded protein kinase (EBV-PK) (Gershburg and Pagano, 2002), which also has previously been shown to play a critical role in viral replication (Gershburg et al., 2007; Murata et al., 2009). Therefore, we inquired whether the inhibition of viral replication by selected PKIs involves a direct inhibition of the EBV-PK activity. To this end, the EBV-PK was expressed as a fusion with a glutathione S-transferase (GST) gene in insect cells infected with a recombinant baculovirus. The purification procedure included an affinity and ion-exchange chromatography steps and resulted in near homogeneous preparation of GST-tagged EBV-PK used in the consequent experiments (not shown). Next, we tested the activity of the GST/EBV-PK at various reaction conditions (Fig. 3). We found that the optimal conditions for the GST/EBV-PK slightly differ from previously reported (Chen et al., 2000; Daikoku et al., 1997; He et al., 1997). We found that the rate of phosphorylation was linear for ~7 min and complete by 20 min. To determine optimal conditions, the reactions were stopped at 5 min and phosphorylation rates were measured by filter-binding assays. Phosphorylation was greatest at physiological pH, with maximal incorporation at about pH 8.0 (Fig. 3D) and significantly reduced at higher pH. The activity was inhibited by salt, with an optimum at 100mM NaCl and with about 25% activity remaining at 0.5M NaCl (Fig. 3C). The activity absolutely required Mn^{2+} , which could not be replaced by Mg^{2+} (Fig. 3B), Ca^{2+} , Zn^{2+} , or Co^{2+} (not shown) at concentrations up to 10mM. The final conditions used in subsequent assays were: 75mM Hepes, pH 8.0, 100mM NaCl, 5mM $MnCl_2$, 1mM dithiothreitol (DTT), 0.1% NP-40, and 50 μ M ATP. To verify that the observed kinase is due to the GST/EBV-PK and not due to a co-purified cellular kinase, an inactive mutant of the EBV-PK, in which an invariable lysine-102 has been mutated into isoleucine, was tested in the optimized conditions and exhibited no detectable activity, whereas the wild type EBV-PK efficiently phosphorylated MBP and itself (Fig. 3A).

3.5 Effects of selected PKIs on GST-BGLF4 kinase activity *in vitro*

Protein kinase inhibitors that exhibited a significant (more than 80%) anti-EBV activity were tested *in vitro* to assess their direct effect on the EBV-PK activity. Purified GST/EBV-PK was incubated with 10 μ M of inhibitors or DMSO, and its activity was measured by filter binding assays at previously optimized conditions. Incubation with K252A served as a positive control for the assays, because we have previously shown that this compound inhibits the EBV-PK activity in a similar assay (Gershburg et al., 2004). Indeed, K252A efficiently inhibited the GST/EBV-PK activity by about 75%. In contrast, other tested PKIs exhibited only negligible inhibitory effects on the GST/EBV-PK activity (Fig. 4). To verify the activity of used compounds, 5,6-dichloro-1- β -D-ribofuranosilbenzimidazole (DRB), apigenin, and 5-Iodotubercidin were incubated with their known target, CKII, and almost completely blocked its activity at significantly lower concentrations (not shown). These results (a) suggest that the anti-EBV activity of PKIs is not mediated through the EBV-PK, and (b) imply that despite encoding its own protein kinase the virus relies on several host cell protein kinases (and potentially several signaling pathways) to attain an efficient infection.

4. DISCUSSION

4.1 BCR-mediated induction of the EBV lytic program and its inhibition by PKIs

Ag binding to BCR activates signaling cascade that involves multiple pathways. In certain EBV-positive BL cell lines, BCR signaling reactivates EBV lytic program, but the contribution of different pathways in viral reactivation is not clearly understood. The present study aimed to analyze the contribution of these different pathways by using a set of protein kinase inhibitors that inhibit components of the several major pathways involved in BCR signaling as well as additional pathways not apparently involved in BCR signaling. A simplified flowchart of the BCR signaling and some inhibitors used in the study are presented in Figure 5.

Out of 80 PKIs used in the study 32 primarily target tyrosine kinases including Syk and Btk, which play a significant role in BCR signaling (Dal Porto et al., 2004; Kurosaki et al., 2010). Only two compounds, Tyrphostin 9 and Erbstatin analog, which inhibit platelet-derived growth factor receptor-associated tyrosine kinase (PDGFRK) and epidermal growth factor receptor-associated tyrosine kinase (EGFRK), respectively, inhibited EBV replication in cells. However, the selectivity of both compounds in our assays was low (TI = 3 and 2, respectively). This lack of selectivity may indicate that the antiviral effect is simply a result of cytotoxicity, in particular for Tyrphostin 9, which has been shown to inhibit cdk2 activity, block cell cycle, and cause apoptosis in addition to inhibiting PDGFRK (Palumbo et al., 1997). Such an assumption is strengthened by the fact that none of the other EGFRK or PDGFRK inhibitors demonstrated any anti-EBV activity. Most surprising however was lack of the effect of Syk and Btk inhibitors. None of the three inhibitors targeting these kinases inhibited EBV replication. Two possible explanations for this phenomenon are (1) the effective inhibitory concentration was not reached (the reported IC₅₀ for one of the Btk inhibitors, LFM-A13, is 17.2 μM), and (2) these kinases are not essential in pathways leading to viral reactivation and the activity of Lyn and participation of other Src family kinases may be sufficient for reactivation of EBV lytic program (Dal Porto et al., 2004).

Broad range PKIs such as Staurosporine, its derivative PKC-412, and K252A expectedly inhibited viral replication, but this effect is likely due to their cytotoxicity (TI = 1, 2, and 6, respectively). The compounds target multiple protein kinases including PKC that has previously been shown to play role in EBV reactivation (Daibata et al., 1990; Davies et al., 1991; Gao et al., 2001; Lazdins et al., 1987) and, in agreement with such a possibility, all three compounds block expression of EBV early protein EA-D (Fig. 2).

The only other compound that inhibited EA-D expression (and likely EBV reactivation) is a PI3K inhibitor wortmannin. PI3K plays an essential role in BCR signaling (Dal Porto et al., 2004; Kurosaki et al., 2010) and EBV reactivation (Iwakiri and Takada, 2004) and hence the effect of wortmannin is not surprising particularly when another PI3K inhibitor, LY294002, similarly showed high anti-EBV activity. The activity of the latter was somewhat less pronounced likely due to the differences in mechanisms of action (Vlahos et al., 1994; Wymann et al., 1996) and the fact that concentration of LY294002 was below its IC₅₀ (Fig. 2B and Table 1). More surprising however was lack of activity of quercetin (on basis of which the LY294002 was synthesized). A traditional PI3K/Akt/mTOR pathway seems to be dispensable for the EBV reactivation since inhibitors of mTOR and Akt had no effect on viral replication.

The study confirmed that PI3K, PKC and MAPK are the key components in a pathway (or pathways) leading to EBV reactivation. Several inhibitors of PKC, NF-κB, and MAPK pathways inhibited EBV replication with different degree of selectivity. More importantly, however, we identified several components that did not affect EBV reactivation or

replication: (a) inhibition of p38MAPK by three specific inhibitors had no effect on viral replication; (b) inhibition of Raf by two inhibitors had no effect on viral replication (even though inhibitors of MEK1/2 and Erk1/2 inhibited it); (c) inhibition of IKK β by SC-514 had no effect, whereas less specific Bay 11-7082 inhibited viral replication suggesting the leading role of IKK α in this process. Taken together, these results suggest that EBV reactivation induced by BCR signaling is achieved by a coordinated activity of several interconnected pathways in which PI3K, PKC, and MAPK pathways play a dominant role.

4.2 *In vitro* activity of the EBV-PK and its inhibition by PKIs

Optimal conditions required for the EBV-PK were somewhat different from other CHPKs tested to date (Daikoku et al., 1997; He et al., 1997). The enzyme's activity peaked at physiological pH and low salt concentrations, and was highly selective in terms of its needs in bivalent ions (Fig. 3). All these are in contrast to preferences to high salt concentrations, relatively high pH, and a relative ion substitution tolerance (Mn²⁺ substitution for Mg²⁺) previously shown for a GST-tagged purified pUL97 of HCMV (He et al., 1997), or lack of pH sensitivity and full activity in Mg²⁺ (other ions were not tested) shown for purified UL13 of HSV-2 (Daikoku et al., 1997). Our data also differs from a previously published analysis of EBV-PK immunoprecipitated from mammalian cells transiently expressing an EBV-PK protein tagged with an EBNA-1-based tag (Chen et al., 2000). The discrepancies between the two datasets are most likely due to the degree of purification; the enzyme used in our studies is highly purified through several chromatography steps and doesn't seem to carry contaminants that possess a detectable kinase activity, whereas the immunoprecipitated complexes used in the other study most likely contained such contaminants which is illustrated by the fact that a mutant with an invariable lysine-102 changed into an alanine (as well as several other similar mutants) was still fully active [Figures 10 and 11 in (Chen et al., 2000)]. While the biological relevance of the differences in optimal conditions for different herpesviral conserved protein kinases is not clear, the study establishes experimental conditions at which the highly purified EBV protein kinase exhibits optimal activity.

Another aspect of the study dealt with the effect of tested protein kinase inhibitors on the activity of EBV-PK *in vitro*. None of the anti-EBV compounds (except for K252A) inhibited the viral protein kinase (Fig. 4). Moreover, we eventually tested all 80 compounds and only few of them exhibited marginal inhibitory effect (10 – 15% relative to DMSO-treated control) (not shown). These observations reiterate the structural “uniqueness” of this kinase (and likely the other CHPKs) in comparison to cellular kinome and raise the possibility of developing a highly specific inhibitor against this protein kinase.

Acknowledgments

We thank Dr. William Halford and Dr. Donald Torry for helpful discussions. This work was supported in part by the National Institutes of Health grant R21-AI072221.

Abbreviations

BCR	B-cell receptor
EBV	Epstein-Barr Virus
CDK	cyclin-dependent kinase
GSK-3β	glycogen synthase kinase 3 β
PI3K	phosphatidylinositol-3-kinase

PCR	polymerase chain reaction
PDGFRK	platelet-derived growth factor receptor-associated tyrosine kinase
EGFRK	epidermal growth factor receptor-associated tyrosine kinase
NF-κB	nuclear factor κ B
PLCγ2	phospholipase C γ 2
MAPK	mitogen-activated protein kinase
Btk	Bruton's tyrosine kinase
PIP2	phosphatidylinositol diphosphate
DAG	diacylglycerol
IP3	inositol triphosphate
PKC	protein kinase C
ERK	extracellular signal-regulated kinase
JNK	c-Jun NH2 terminal kinase
CHPK	conserved herpesvirus protein kinase
HCMV	human cytomegalovirus
NGIC-I	non-glucosidic indolocarbazole I
BL	Burkitt's lymphoma
CDK	cyclin-dependent kinase
DMSO	dimethylsulfoxide
ACV	acyclovir
qPCR	quantitative real-time PCR
PKI	protein kinase inhibitor
GST	glutathione-S-transferase
MBP	myelin basic protein
DTT	dithiothreitol
MEK1/2	mitogen-activated protein kinase kinases 1 and 2
CKI	casein kinase I
CKII	casein kinase II
DRB	5,6-dichloro-1 β -D-ribofuranosilbenzimidazole

REFERENCES

- Adamson AL, Kenney SC. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. *Virology*. 1998; 251:187–197. [PubMed: 9813214]
- Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. *Biochem J*. 1993; 296(Pt 2):297–301. [PubMed: 8257416]
- Asai R, Kato A, Kato K, Kanamori-Koyama M, Sugimoto K, Sairenji T, Nishiyama Y, Kawaguchi Y. Epstein-Barr virus protein kinase BGLF4 is a virion tegument protein that dissociates from virions

- in a phosphorylation-dependent process and phosphorylates the viral immediate-early protein BZLF1. *J Virol.* 2006; 80:5125–5134. [PubMed: 16698993]
- Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N-benzoylstauroporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. *Leuk Lymphoma.* 2005; 46:899–908. [PubMed: 16019536]
- Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y. Induction of a common pathway of apoptosis by staurosporine. *Exp Cell Res.* 1994; 211:314–321. [PubMed: 8143779]
- Bilder GE, Krawiec JA, McVety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrone MH, Schreiber AB. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. *Am J Physiol.* 1991; 260:C721–730. [PubMed: 1850195]
- Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith IA, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW. Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole L-Riboside with a Unique Mode of Action. *Antimicrob Agents Chemother.* 2002; 46:2365–2372. [PubMed: 12121906]
- Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. *J Virol.* 2003; 77:8532–8540. [PubMed: 12857922]
- Chen MR, Chang SJ, Huang H, Chen JY. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. *J Virol.* 2000; 74:3093–3104. [PubMed: 10708424]
- Chin LS, Murray SF, Doherty PF, Singh SK. K252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c. *Cancer Invest.* 1999; 17:391–395. [PubMed: 10434949]
- Daibata M, Humphreys RE, Takada K, Sairenji T. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. *J Immunol.* 1990; 144:4788–4793. [PubMed: 2161880]
- Daikoku T, Shibata S, Goshima F, Oshima S, Tsurumi T, Yamada H, Yamashita Y, Nishiyama Y. Purification and characterization of the protein kinase encoded by the UL13 gene of herpes simplex virus type 2. *Virology.* 1997; 235:82–93. [PubMed: 9300039]
- Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. *Mol Immunol.* 2004; 41:599–613. [PubMed: 15219998]
- Darr CD, Mauser A, Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. *J Virol.* 2001; 75:6135–6142. [PubMed: 11390615]
- Davies AH, Grand RJ, Evans FJ, Rickinson AB. Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. *J Virol.* 1991; 65:6838–6844. [PubMed: 1658377]
- Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem J.* 2000; 351:95–105. [PubMed: 10998351]
- Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412--a protein kinase inhibitor with a broad therapeutic potential. *Anticancer Drug Des.* 2000; 15:17–28. [PubMed: 10888033]
- Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. *Mol Diagn.* 2001; 6:279–289. [PubMed: 11774193]
- Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J Biol Chem.* 1998; 273:18623–18632. [PubMed: 9660836]
- Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. *Embo J.* 2000; 19:3080–3089. [PubMed: 10856251]
- Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Pazhanisamy S, Fleming MA, Galullo V, Su MS, Wilson KP. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. *Protein Sci.* 1998; 7:2249–2255. [PubMed: 9827991]

- Gao X, Ikuta K, Tajima M, Sairenji T. 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. *Virology*. 2001; 286:91–99. [PubMed: 11448162]
- Gershburg E, Hong K, Pagano JS. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. *Antimicrob Agents Chemother*. 2004; 48:1900–1903. [PubMed: 15105156]
- Gershburg E, Pagano JS. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. *J Virol*. 2002; 76:998–1003. [PubMed: 11773375]
- Gershburg E, Pagano JS. Conserved herpesvirus protein kinases. *Biochim Biophys Acta*. 2008; 1784:203–212. [PubMed: 17881303]
- Gershburg E, Raffa S, Torrisi MR, Pagano JS. Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus. *J Virol*. 2007; 81:5407–5412. [PubMed: 17360761]
- Gershburg S, Murphy L, Marschall M, Gershburg E. Key motifs in EBV (Epstein-Barr virus)-encoded protein kinase for phosphorylation activity and nuclear localization. *Biochem J*. 2010; 431:227–235. [PubMed: 20704565]
- Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. Rottlerin, a novel protein kinase inhibitor. *Biochem Biophys Res Commun*. 1994; 199:93–98. [PubMed: 8123051]
- Hamirally S, Kamil JP, Ndassa-Colday YM, Lin AJ, Jahng WJ, Baek MC, Noton S, Silva LA, Simpson-Holley M, Knipe DM, Golan DE, Marto JA, Coen DM. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. *PLoS Pathog*. 2009; 5:e1000275. [PubMed: 19165338]
- Han Z, Pantazis P, Lange TS, Wyche JH, Hendrickson EA. The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C. *Cell Death Differ*. 2000; 7:521–530. [PubMed: 10822275]
- He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. *J Virol*. 1997; 71:405–411. [PubMed: 8985364]
- Hers I, Tavaré JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. *FEBS Lett*. 1999; 460:433–436. [PubMed: 10556511]
- Iwakiri D, Takada K. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. *J Immunol*. 2004; 172:1561–1566. [PubMed: 14734735]
- Jacob T, Van den Broeke C, Favoreel HW. Viral serine/threonine protein kinases. *J Virol*. 2011; 85:1158–1173. [PubMed: 21084474]
- Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science*. 2002; 298:1911–1912. [PubMed: 12471242]
- Kawaguchi Y, Kato K. Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. *Rev Med Virol*. 2003; 13:331–340. [PubMed: 12931342]
- Kieff, E.; Rickinson, AB. Epstein-Barr virus and its replication. In: Knipe, DM.; Howley, PM., editors. *Fields Virology*. 5th ed.. Lippinkott-Williams & Wilkins; Philadelphia: 2007. p. 2603-2654.
- Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. *Annu Rev Immunol*. 2010; 28:21–55. [PubMed: 19827951]
- Lazdins J, Zompetta C, Grimaldi S, Barile G, Venanzoni M, Frati L, Faggioni A. TPA induction of Epstein-Barr virus early antigens in Raji cells is blocked by selective protein kinase-C inhibitors. *Int J Cancer*. 1987; 40:846–849. [PubMed: 2826340]
- Liu SF, Wang H, Lin XC, Xiang H, Deng XY, Li W, Tang M, Cao Y. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. *Cell Biol Int*. 2008; 32:1006–1013. [PubMed: 18579417]
- Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. *J Gen Virol*. 2002; 83:1013–1023. [PubMed: 11961255]

- Massillon D, Stalmans W, van de Werve G, Bollen M. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. *Biochem J.* 1994; 299(Pt 1):123–128. [PubMed: 8166629]
- McKenna JP, Hanson PJ. Inhibition by Ro 31-8220 of acid secretory activity induced by carbachol indicates a stimulatory role for protein kinase C in the action of muscarinic agonists on isolated rat parietal cells. *Biochem Pharmacol.* 1993; 46:583–588. [PubMed: 8363630]
- Mori T, Sairenji T. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1. *Virus Genes.* 2006; 32:327–334. [PubMed: 16732486]
- Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. *Virology.* 2009; 389:75–81. [PubMed: 19427010]
- Oussaief L, Ramirez V, Hippocrate A, Arbach H, Cochet C, Proust A, Raphael M, Khelifa R, Joab I. NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1. *J Virol.* 2011; 85:6502–6512. [PubMed: 21507981]
- Overton HA, McMillan DJ, Klavinskis LS, Hope L, Ritchie AJ, Wong-kai-in P. Herpes simplex virus type 1 gene UL13 encodes a phosphoprotein that is a component of the virion. *Virology.* 1992; 190:184–192. [PubMed: 1326802]
- Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron N, Levitzki A, Ben-Yehuda D. The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. *Cancer Res.* 1997; 57:2434–2439. [PubMed: 9192822]
- Peng L, Wu TT, Tchieu JH, Feng J, Brown HJ, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jamieson C, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. *The Journal of general virology.* 2010; 91:463–469. [PubMed: 19864499]
- Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. *J Biol Chem.* 1997; 272:21096–21103. [PubMed: 9261113]
- Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. *J Virol.* 1999; 73:5663–5670. [PubMed: 10364316]
- Rickinson, AB.; Kieff, ED. Epstein-Barr Virus. In: Knipe, DM.; Howley, PM., editors. *Fields Virology.* 5th ed.. Lippinkott-Wilms & Wilkins; Philadelphia: 2007. p. 2655-2700.
- Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rotterlin: therapeutic implications for B-CLL. *Leukemia.* 2006; 20:514–520. [PubMed: 16437144]
- Satoh T, Hoshikawa Y, Satoh Y, Kurata T, Sairenji T. The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells. *Virus Genes.* 1999; 18:57–64. [PubMed: 10334038]
- Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. *J Med Chem.* 1999; 42:2909–2919. [PubMed: 10425100]
- Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. *Int J Cancer.* 1984; 33:27–32. [PubMed: 6319296]
- Takada K, Horinouchi K, Ono Y, Aya T, Osato T, Takahashi M, Hayasaka S. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. *Virus Genes.* 1991; 5:147–156. [PubMed: 1647567]
- Tovey MG, Lenoir G, Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. *Nature.* 1978; 276:270–272. [PubMed: 213727]
- Umezawa K, Hori T, Tajima H, Imoto M, Isshiki K, Takeuchi T. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. *FEBS Lett.* 1990; 260:198–200. [PubMed: 2298299]

- van Zeijl M, Fairhurst J, Baum EZ, Sun L, Jones TR. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. *Virology*. 1997; 231:72–80. [PubMed: 9143304]
- Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J Biol Chem*. 1994; 269:5241–5248. [PubMed: 8106507]
- Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. Maribavir inhibits Epstein-Barr viral transcription in addition to viral DNA replication. *J Virol*. 2009
- Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. *Antimicrob Agents Chemother*. 2003; 47:2186–2192. [PubMed: 12821466]
- Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. *Mol Cell Biol*. 1996; 16:1722–1733. [PubMed: 8657148]
- Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. *J Virol*. 1999; 73:7271–7277. [PubMed: 10438815]
- Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. *Cancer Res*. 1999; 59:2566–2569. [PubMed: 10363974]

Highlights for the following manuscript

“Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr Virus” by Ria Goswami, Svetlana Gershburg, Ashley Satorius, and Edward Gershburg

- protein kinase inhibitors of PI3K, MAPK, and NF- κ B pathways inhibit EBV replication
- out of 80 tested protein kinase inhibitors only K252A inhibited activity of EBV-PK
- PI3K inhibitors seem to act during the reactivation; MAPK inhibitor U0126 acts later

Figure 1. EBV replication in Akata cells is inhibited by selected protein kinase inhibitors
 EBV lytic program was induced in Akata cells by IgG treatment in the presence of 10 μ M of each PKI. Forty-eight hours after induction, total genomic DNA was isolated and EBV genomes were enumerated by qPCR. Results are expressed as percentage of inhibition relative to the DMSO treatment. Means $\pm$ sem of 3 independent experiments are shown. Names of the compounds selected for further studies are shown. The selection cut-off values of 50 and 80% inhibition are marked by dashed lines. DMSO-treated uninduced cell and ACV-treatment served as negative controls. P-values are: *- $p < 0.05$, ** - $p < 0.01$, *** - $p < 0.001$.

Figure 2. Effect of PKIs inhibiting EBV replication on the EBV EA-D expression

EBV lytic program was induced in Akata cells by IgG treatment in the presence of 10 μM (A) or 1 μM (B) of selected protein kinase inhibitors. Twenty-four hours after induction, whole-cell lysates were prepared and subjected to SDS-PAGE. EA-D expression was assessed by immunoblotting.

Figure 3. Optimization of reaction conditions for GST-tagged EBV-PK

(A) One pmole of wild-type or inactive EBV-PK (PK and PK-K102I, respectively) were incubated with 1 μg of MBP as described in Materials and Methods and subjected to SDS-PAGE. The gel was stained with Coomassie R-250 (CBB) and the ^{32}P incorporation (^{32}P) was assessed on a phosphor imager. (B - D) EBV-PK was incubated with MBP as described above except that divalent cation concentrations (B), NaCl concentrations (C), and pH (D) varied as indicated. The ^{32}P incorporation was measured by filter binding assays.

Figure 4. Effect of the PKIs inhibiting EBV replication on the EBV-PK activity in vitro EBV-PK was incubated with MBP at optimal conditions established earlier and in the presence of DMSO or 10 μ M of selected inhibitors. The 32 P incorporation was measured by filter binding assays and is expressed as percentage of kinase activity relative to the DMSO control. Means $\pm$ sem of 3 independent experiments are shown.

Figure 5. Diagram of pathways activated in BCR signaling and selected inhibitors affecting these pathways

Protein components of the pathways are shown as light grey ovals, non-protein component are shown as white rectangles. PKIs that inhibited EBV replication are shown in dark grey rectangles; PKIs that had no effect on EBV replication are shown in patterned rectangles.

Table 1
Selectivity of PKIs inhibiting EBV replication

EBV lytic program was induced in Akata cells by IgG treatment in the presence of 0.0005 - 30 μ M of selected PKIs. Forty-eight hours after induction, EBV genomes were enumerated by qPCR and cell viability was measured by a modified MTS assay. Cytotoxic and inhibitory concentrations inhibiting the cellular activity and viral replication by 50% (CC50 and IC50) were calculated in Prism 5 (GraphPad) using a four parameters sigmoidal dose-response curve. Therapeutic index (TI) represents the CC50/IC50 ratio.

	CC50 (μ M)	IC50 (μ M)	TI
U-0126	7.376	0.552	13
Staurosporine	0.004	0.005	1
Tyrphostin 9	0.573	0.217	3
PKC-412	0.056	0.031	2
LY 294002	6.160	1.835	3
Wortmannin	4.686	0.367	13
Ro 31-8220	1.147	0.398	3
5-Iodotubercidin	1.121	0.890	1
Rottlerin	1.005	0.983	1
Erbstatin analog	3.896	2.373	2
BAY 11-7082	2.636	0.208	13
Kenpaullone	5.127	0.681	8
K252A	0.080	0.014	6